Disclosed are inhibitors for the β-catenin/T-cell factor interaction. The inhibitors are selective for β-catenin/T-cell factor over β-catenin/cadherin and β-catenin/APC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.
公开了β-连环蛋白/T细胞因子相互作用的
抑制剂。这些
抑制剂对β-连环蛋白/T细胞因子的选择性高于β-连环蛋白/
钙粘蛋白和β-连环蛋白/APC相互作用。还公开了使用所述化合物治疗癌症的方法。